V.P. Stus

6.7k total citations · 2 hit papers
47 papers, 1.7k citations indexed

About

V.P. Stus is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Epidemiology. According to data from OpenAlex, V.P. Stus has authored 47 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 11 papers in Epidemiology. Recurrent topics in V.P. Stus's work include Renal cell carcinoma treatment (19 papers), Renal and related cancers (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). V.P. Stus is often cited by papers focused on Renal cell carcinoma treatment (19 papers), Renal and related cancers (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). V.P. Stus collaborates with scholars based in United States, Ukraine and Russia. V.P. Stus's co-authors include Thomas E. Hutson, С Х Аль-Шукри, Brad Rosbrook, Nicholas J. Vogelzang, Frédéric Pouliot, Elizabeth R. Plimack, Brian I. Rini, Rustem Gafanov, Ray McDermott and Dmitry Nosov and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.

In The Last Decade

V.P. Stus

28 papers receiving 1.6k citations

Hit Papers

Pembrolizumab plus axitinib versus sunitinib monotherapy ... 2019 2026 2021 2023 2020 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
    2020 498 citations Thomas Powles, Elizabeth R. Plimack et al. The Lancet Oncology profile →
  2. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
    2019 284 citations V.P. Stus, Keith S. Kaye et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V.P. Stus United States 12 1.1k 638 626 441 318 47 1.7k
Mallika Lala United States 13 153 0.1× 500 0.8× 120 0.2× 80 0.2× 181 0.6× 25 936
Helen Bhattacharyya United States 15 402 0.4× 409 0.6× 212 0.3× 176 0.4× 13 0.0× 39 953
Michael Cullen United Kingdom 18 487 0.5× 964 1.5× 248 0.4× 116 0.3× 40 0.1× 42 1.4k
Tomotaka Ugai Japan 15 164 0.2× 662 1.0× 318 0.5× 183 0.4× 25 0.1× 69 1.4k
Aikaterini Mastoraki Greece 18 302 0.3× 311 0.5× 276 0.4× 119 0.3× 35 0.1× 81 1.1k
Junshik Hong South Korea 25 498 0.5× 685 1.1× 325 0.5× 130 0.3× 11 0.0× 179 2.0k
Ki‐Seong Eom South Korea 25 96 0.1× 614 1.0× 427 0.7× 65 0.1× 39 0.1× 188 2.3k
Marco Vivarelli Italy 21 378 0.4× 363 0.6× 188 0.3× 94 0.2× 36 0.1× 62 1.7k
C Poole United Kingdom 9 60 0.1× 388 0.6× 776 1.2× 203 0.5× 10 0.0× 12 1.2k
J.W.R. Nortier Netherlands 14 105 0.1× 228 0.4× 60 0.1× 87 0.2× 54 0.2× 43 652

Countries citing papers authored by V.P. Stus

Since Specialization
Citations

This map shows the geographic impact of V.P. Stus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V.P. Stus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V.P. Stus more than expected).

Fields of papers citing papers by V.P. Stus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V.P. Stus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V.P. Stus. The network helps show where V.P. Stus may publish in the future.

Co-authorship network of co-authors of V.P. Stus

This figure shows the co-authorship network connecting the top 25 collaborators of V.P. Stus. A scholar is included among the top collaborators of V.P. Stus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V.P. Stus. V.P. Stus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).
2.
Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.
3.
4.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2024). Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(16_suppl). 4505–4505. 8 indexed citations
5.
6.
7.
Albigès, Laurence, Howard Gurney, Vagif Atduev, et al.. (2023). Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet Oncology. 24(8). 881–891. 73 indexed citations
8.
Lee, Chung‐Han, Howard Gurney, Vagif Atduev, et al.. (2023). First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.. Journal of Clinical Oncology. 41(16_suppl). 4518–4518. 1 indexed citations
9.
Rini, Brian I., Elizabeth R. Plimack, V.P. Stus, et al.. (2023). Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.. Journal of Clinical Oncology. 41(17_suppl). LBA4501–LBA4501. 45 indexed citations
10.
Powles, Thomas, Elizabeth R. Plimack, V.P. Stus, et al.. (2022). Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.. Journal of Clinical Oncology. 40(16_suppl). 4513–4513. 4 indexed citations
11.
Stus, V.P., et al.. (2021). Epidemiological features of chronic cystitis in the capital megapolis. 25(2). 1 indexed citations
12.
Stus, V.P., et al.. (2021). Socio-psychological image of the modern intern (educational and social research). 25(1). 71–80. 1 indexed citations
13.
Powles, Thomas, Elizabeth R. Plimack, Denis Soulières, et al.. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology. 21(12). 1563–1573. 498 indexed citations breakdown →
14.
Stus, V.P., et al.. (2020). Qualities of thinking in interns of various specialties. 24(2). 1 indexed citations
15.
16.
17.
Stus, V.P., et al.. (2019). The role of lead in the etiopathogenesis of male fertility reduction.. PubMed. 71(6). 1155–1160. 6 indexed citations
18.
19.
Hutson, Thomas E., С Х Аль-Шукри, V.P. Stus, et al.. (2016). Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical Genitourinary Cancer. 15(1). 72–76. 49 indexed citations
20.
Hutson, Thomas E., Vladimir Lesovoy, С Х Аль-Шукри, et al.. (2013). Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. The Lancet Oncology. 14(13). 1287–1294. 320 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mallika Lala Breakdown of academic impact, for papers by Helen Bhattacharyya Breakdown of academic impact, for papers by Michael Cullen Breakdown of academic impact, for papers by Tomotaka Ugai Breakdown of academic impact, for papers by Aikaterini Mastoraki Breakdown of academic impact, for papers by Junshik Hong Breakdown of academic impact, for papers by Ki‐Seong Eom Breakdown of academic impact, for papers by Marco Vivarelli Breakdown of academic impact, for papers by C Poole Breakdown of academic impact, for papers by J.W.R. Nortier
Rankless by CCL
2026